98%
921
2 minutes
20
Objectives: The size of the population of men who have sex with men (MSM) who may be eligible for HIV pre-exposure prophylaxis (HIV-PrEP) in England remains unknown. To plan for a national PrEP implementation trial, we estimated the number of MSM attending sexual health clinics (SHCs) that may be eligible for HIV-PrEP in England.
Methods: Sexually transmitted infection (STI) surveillance data from 2010 to 2015 from the GUMCAD surveillance system were used to estimate the annual number of HIV-negative MSM who may be eligible for HIV-PrEP in England. Based on national eligibility criteria, we identified HIV-negative MSM attending SHCs with a HIV-negative test in the past year and used diagnosed bacterial STI (past year) in this group as a proxy for condomless sex and eligibility for HIV-PrEP. We estimated HIV incidence per 100 person-years (py) in these groups in 2014.
Results: During 2010-2015, the number of HIV-negative MSM attending SHCs with a HIV-negative test in the past year doubled from 14 643 to 29 023, and HIV incidence in this group was 1.9 (95% CI 1.6 to 2.2) per 100 py in 2014. In the same period, the subgroup with a bacterial STI diagnosis (past year), and therefore considered potentially eligible for HIV-PrEP in this analysis, increased from 4365 (30%) to 10 276 (35%). HIV incidence in this subgroup was 3.3 (95% CI 2.7 to 4.0) per 100 py in 2014.
Conclusions: In 2015, approximately 10 000 HIV-negative MSM were considered potentially eligible for HIV-PrEP based on clinic history in GUMCAD. These data were used to inform the initial recruitment target for the PrEP Impact Trial and will inform future evaluations at a population level.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/sextrans-2019-054009 | DOI Listing |
Sex Transm Dis
July 2025
Division of STD Prevention, Centers for Disease Control and Prevention.
Background: We sought to determine real-world effectiveness of doxycycline post-exposure prophylaxis (doxy PEP) in reducing sexually transmitted infections (STI) among men who have sex with men attending an HIV pre-exposure prophylaxis (HIV PrEP) clinic in Philadelphia.
Methods: Data from eligible HIV PrEP patients who did and did not receive doxy PEP from September 1, 2019-December 31, 2023 were analyzed. We used a cohort study design and Cox models to estimate associations between doxy PEP receipt and incident gonorrhea (GC), chlamydia (CT), and/or syphilis.
J Virus Erad
September 2025
Africa Health Research Institute, KwaZulu-Natal, South Africa.
Background: Guidelines for Hepatitis B treatment released by the World Health Organization in 2024 include the potential for use of dual therapy, combining tenofovir with either emtricitabine or lamivudine. These fixed-dose combinations are also used for Pre-Exposure Prophylaxis (PrEP) in people at risk of Human Immunodeficiency Virus (HIV). We hypothesize that pre-existing HIV PrEP programmes can support access to HBV testing and treatment.
View Article and Find Full Text PDFInt J Drug Policy
September 2025
Division of Hepatology, Department of Medicine, Faculty of Health Sciences and Groote Schuur Hospital, University of Cape Town, South Africa. Electronic address:
Background: The burden of viral hepatitis and HIV in sub-Saharan Africa is substantial with an estimated 64.7 million living with hepatitis B virus (HBV), 8 million with hepatitis C virus (HCV) and 20.8 million people living with HIV infection.
View Article and Find Full Text PDFSex Transm Infect
June 2025
Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, The Netherlands.
Objectives: Among users of oral HIV pre-exposure prophylaxis (PrEP), condom use is low and incidence of sexually transmitted infections (STIs) is high, hence guidelines recommend STI screening every 3-6 months. Identifying individuals with higher asymptomatic STI risk for targeted screening may offer an opportunity to reduce the burden of STI screening.
Methods: In the Netherlands, PrEP has been offered through the National PrEP Pilot Program since 2019, which includes screening every 3 months.
Introduction: The off-label use of doxycycline to prevent certain sexually transmitted infections (STIs), outside controlled research environments, has been occurring for several years.
Purpose Of The Study: The objective of this study was to describe the off-label use of doxycycline as a preventive treatment for STIs by conducting a review of the literature, including analysis of a social network.
Results: In total, 11 eligible references were identified, comprising 9 letters and 2 original articles.